SURVIVAL ANALYSIS OF NEWLY DIAGNOSED TRANSPLANTELIGIBLE MULTIPLE MYELOMA PATIENTS ENROLLED IN THE RANDOMIZED FORTE TRIAL

HIGH LEVELS OF CIRCULATING PLASMA CELLS ARE AN INDEPENDENT HIGH-RISK FEATURE IN MULTIPLE MYELOMA PATIENTS AND THEIR PROGNOSTIC IMPACT IS MODULATED BY THE ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY

IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS

IMPACT OF IMAGING FDG PET/CT MINIMAL RESIDUAL DISEASE ASSESSMENT ON OUTCOMES AND COMPLEMENTARITY WITH MULTIPARAMETER FLOW CYTOMETRY IN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ENROLLED IN THE PHASE II RANDOMIZED FORTE TRIAL

POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB (POLA+BR) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): UPDATED RESULTS OF A PHASE IB/II RANDOMIZED STUDY AND PRELIMINARY RESULTS OF A SINGLE ARM EXTENSION

A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY

PEVONEDISTAT (P) PLUS AZACITIDINE (A) VS A ALONE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS): EFFICACY AND SAFETY RESULTS FROM STUDY P-2001 (NCT02610777)

MINIMAL RESIDUAL DISEASE (MRD)-DRIVEN TREATMENT PERSONALIZATION WITH SEQUENTIAL ADDITION OF IBRUTINIB (IBR) TO VENETOCLAX (VEN) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): THE IMPROVE STUDY

ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE (DEX) IN 55 PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH EXTRAMEDULLARY DISEASE (EMD)—SUBGROUP ANALYSIS

UPDATED RESULTS OF THE ASPEN TRIAL FROM A COHORT OF PATIENTS WITH MYD88 WILD-TYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM)

OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA (PMBCL) AFTER DIFFERENT INDUCTION REGIMENS IN THE PRELIMINARY ANALYSIS OF THE IELSG37 TRIAL

HIGH DOSE THERAPY AND STEM CELL RESCUE IN MANTLE CELL LYMPHOMA: THE MCL0208 TRIAL FROM FONDAZIONE ITALIANA LINFOMI

DIRECT-ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV-ASSOCIATED INDOLENT NON-HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI